



Multifocal locules including the anterior mediastinum side as a surgical indicator in pleural infection

Takashi Sakai^{1^}, Atsushi Sano¹, Hiroshige Shimizu², Yoko Azuma¹, Naohisa Urabe², Kazutoshi Isobe², Susumu Sakamoto², Yujiro Takai², Yoshitaka Murakami³, Kazuma Kishi², Akira Iyoda¹

¹Division of Chest Surgery, Department of Surgery, Toho University School of Medicine, Tokyo, Japan; ²Division of Respiratory Medicine, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan; ³Department of Medical Statistics, Toho University School of Medicine, Tokyo, Japan

Contributions: (I) Conception and design: T Sakai, A Sano, H Shimizu, Y Azuma, N Urabe, A Iyoda; (II) Administrative support: A Sano, Y Azuma, K Isobe, S Sakamoto, Y Takai, K Kishi, A Iyoda; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: T Sakai, A Sano, H Shimizu, N Urabe; (V) Data analysis and interpretation: T Sakai, A Sano, H Shimizu, N Urabe; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Akira Iyoda. Division of Chest Surgery, Department of Surgery, Toho University School of Medicine, 6-11-1, Omorinishi, Ota-ku, Tokyo 143-8541, Japan. Email: aiyoda@med.toho-u.ac.jp.

Background: The indication for and the timing of surgery in patients with pleural infection remains unclear. Determining the need for surgery in patients with pleural infection may help in the early consultation of surgeons.

Methods: Data of 167 consecutive patients with pleural infection were retrospectively reviewed. To detect a surgical indicator, the variables of patients who required surgery were compared with those of patients who were cured by non-surgical therapy (n=94) and patients resistant to the non-surgical therapy (n=73; 62 underwent surgery, and 11 showed recurrence or disease-related death after non-surgical treatment). Prognosis and timing of surgery were analyzed by comparing three groups: patients who underwent surgery within 7 days of admission (n=33), patients who underwent surgery after 7 days of admission (n=29), and patients who underwent non-surgical therapy (n=105).

Results: The presence of multifocal locules, including a locule on the anterior mediastinum side (LAMS) was a significant indicator of resistance to initial non-surgical therapy, as compared to the absence of locules (P<0.0001), a single locule (P<0.0001), or multifocal locules without a LAMS (P=0.0041). Recurrence and mortality were not observed in the patients who underwent surgery within 7 days of admission, and the hospitalization period (P=0.0071) and duration of C-reactive protein (CRP) improvement (P<0.0001) were significantly shorter in these patients compared with those who that underwent surgery after 7 days.

Conclusions: In patients with pleural infection, the presence of multifocal locules, including a LAMS, was associated with resistance to non-surgical therapy. Early surgery should be considered for these patients to shorten the hospitalization period and improve the prognosis.

Keywords: Pleural infection; empyema; surgical indicator; multifocal locules; locule on anterior mediastinum side

Submitted Nov 15, 2021. Accepted for publication Mar 31, 2022.

doi: 10.21037/jtd-21-1812

View this article at: <https://dx.doi.org/10.21037/jtd-21-1812>

[^] ORCID: 0000-0003-2724-530X.

Introduction

Although the treatment strategy for pleural infection was updated in the most recent guidelines, surgery is indicated for cases resistant to non-surgical treatment (1,2). Andrews classified pleural infection based on the intrathoracic condition as exudative, fibropurulent, or organized; these stages were dependent mainly on the duration of the illness (3). Patients in the exudative and early fibropurulent stage can be treated by non-surgical therapy, including tube drainage, antibiotics, and intrapleural fibrinolytic therapy; surgical management is often required for the advanced fibropurulent and organized stages of empyema (2,4,5). However, these clinical stages cannot be defined exactly because of the difficulty in diagnosing intrathoracic phases based only on clinical findings and the fact that the disease duration depends on the self-reported appearance of symptoms (6).

Light classified pleural parapneumonic effusions and empyema according to the anatomical, bacteriological, and chemical characteristics of the effusion and concluded that surgical management is often required for patients showing an accumulation of pus (classified as empyema) and multiple locules (7,8). However, Light's criteria were reported to be unreliable in patients with multiple locules because of the variations in chemical and bacteriological characteristics of the locules (9-11). Moreover, non-surgical management was associated with a higher recurrence rate of empyema (12); thus, surgical management is desirable for selected patients with pleural infection.

The treatment strategy for pleural infection and the surgical indications remain topics of debate. Wozniak *et al.* determined that failure of the first procedure was strongly related to the prognosis of empyema patients and recommended early consultation with a surgeon (13). Thus, identifying additional predictors of surgical conversion for pleural infection, including specific imaging results, may facilitate decision-making regarding early surgery and the formulation of a treatment strategy for improving the prognosis. Our institution has used a guideline-based strategy to treat many patients with pleural infection over a long period; therefore, we retrospectively analyzed these patients to identify the predictors for surgical intervention in pleural infection. We present the following article in accordance with the STROBE reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1812/rc>).

Methods

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by ethics committee of Toho University Omori Medical Center (No. M20218_19218) and informed consent was taken from all the patients.

Patients

We retrospectively analyzed two regularly updated medical databases of the Division of Chest Surgery, Department of Surgery, and Division of Respiratory Medicine, Department of Internal Medicine, Toho University School of Medicine. We extracted the data of the patients who were treated for pleural infection between January 2008 and December 2020 at Toho University Omori Medical Center from the databases. All participants provided informed consent for using their data for analyses in the form of an opt-out feature on the website of the center. The study protocol was approved by the Ethics Committee of Toho University Omori Medical Center (approval number: M20218_19218).

Evaluation of pleural infection

Acute empyema was defined as a pleural infection with symptoms appearing within 3 months. All cases were diagnosed to acute empyema via blood test, chest X-ray, ultrasound, computed tomography (CT) scan, and thoracentesis, and classified based on the American College of Chest Physicians (ACCP) category and Light's classification. Patients having images or surgical findings for chronic empyema were excluded from the study dataset. Patients with iatrogenic empyemas, such as empyema occurring after neck and chest surgery, port-site infection, or lung abscess after bronchoscopic biopsy, were also excluded because the infection route and treatment strategy differed from pleural parapneumonic effusions and empyema. Patients with empyema due to *Aspergillus* infections and tuberculosis were also excluded because their treatment differed from pleural infection caused by bacteria.

Image findings

Image findings in CT scans, including multifocal locules, locules on the mediastinal side (*Figure 1*), pleural microbubbles (14), and the split pleura sign (15), were




Figure 1 Image findings of (A) multifocal locules (arrows) and (B) LAMS (circle) in a patient with pleural infection. LAMS, locule on the anterior mediastinum side.

reviewed by two different respiratory doctors and confirmed by all co-authors. A “locule” was defined by an isolated fluid retention in the thoracic cavity on the scan; these were confirmed by recalibrating multi-planar reconstruction images in the axial, sagittal, and coronal views. If isolated locule on the anterior mediastinum side (LAMS), locules in the space surrounded by the lung, anterior mediastinum, and chest wall were observed, we defined the condition as LAMS.

Treatment strategy and patient follow-up

The treatment strategy was based on Light’s classification (Figure 2). All patients underwent thoracentesis and initial treatment with antibiotic therapy. Generally, ampicillin and β -Lactam antibiotics were chosen; patients with systemic inflammatory response syndrome and sepsis received initial broad-spectrum antibiotic treatment using carbapenem or piperacillin and tazobactam.

After placing tube drain, irrigation was performed every day using 500 or 1,000 mL of saline depending on the size of the cavity. Thrombolytic therapy was performed using 120,000 units of urokinase on day 1 and 60,000 units on days 2 and 3. Irrigation and thrombolytic therapy were not performed or were discontinued for patients diagnosed with or suspected to have a fistula. Monotherapy using urokinase was selected for thrombolytic therapy because combination therapy using tissue plasminogen activator and DNase was not allowed in Japan (16).

Tube thoracostomy was performed under fluoroscopy or CT in addition to ultrasound; tube thoracostomy with multiple tubes was performed for patients with multifocal locules who were resistant to single-tube thoracostomy. If tube thoracostomy was not possible due to a lack of space or adhesion of the lungs, only thoracentesis and administration of antibiotics were performed initially.

Patients who showed improvement after the initial treatment were discharged with oral antibiotics and outpatient follow-up. A surgical approach was considered after a respiratory-center discussion if the locules persisted and the symptoms, condition, or inflammatory data did not improve or worsened. If the respiratory or general condition worsened rapidly or led to sepsis, early surgical management was considered.

All thoracotomy procedures were performed via two- or three-port approaches. The surgical procedure was selected according to the thoracoscopy findings. Irrigation with complete video-assisted thoracoscopic surgery (VATS) or a two-port approach with wounds of 5–8 and 1 cm was performed for patients with exudative and early-phase fibropurulent stage empyema; patients with late-phase fibropurulent and organized-stage empyema underwent decortication with wounds of 8–15 and 1–5 cm.

Antibiotics were continued until clinical condition, radiological findings, and inflammatory parameters including the white blood cell count and C-reactive protein level, improved. Patients who underwent surgery were followed-up for at least 6 months postoperatively. Follow-

	Light classification	Initial treatment				Surgical treatment
		Antibiotics	Thoracentesis	Tube thoracostomy*	Irrigation and thrombolytics**	
1	Non-significant pleural effusion	○	△	-	-	Improved
2	Typical parapneumonic pleural effusion	○	○	△	-	↗ Outpatient follow-up
3	Borderline complex pleural effusion	○	○	○	△	
4	Simple complicated pleural effusion	○	○	○	△	↘ Unimproved***
5	Complex complicated pleural effusion	○	○	○	○	
6	Simple empyema	○	○	○	○	↘ Surgical treatment
7	Complex empyema	○	○	○	○	

Figure 2 Treatment strategy for pleural infections at our institution. Non-surgical treatments are initially selected based on Light's classification. ○: performed; △: performed with the following exceptions: only thoracentesis is performed for patients with type 1; a tube thoracostomy is performed for patients with type 3 and above (and objectively selected for patients with type 2). If a tube thoracostomy is not possible due to a lack of space or adhesion of the lungs, only thoracentesis and administration of antibiotics are performed initially (*). Irrigation and thrombolytics are used for patients with type 5 and above (and objectively selected for patients with type 3 and 4), except for the patients who are diagnosed with or suspected to have a fistula (**). If the patient improves after the initial treatment, patients are discharged with oral antibiotics and outpatient follow-up. Surgery is performed if the locule(s) remain and are not improved after the initial treatment, or if the symptoms, condition, or inflammation worsen. If the respiratory or general condition worsens rapidly or leads to sepsis, early surgery is performed to control the infection (***).

up assessments were terminated for patients who showed improvements in the inflammatory parameters and overall condition after the initial treatment and for patients who were re-administered antibiotics on presenting to our hospital for other reasons; the re-administration duration was included in the follow-up period.

Statistical analysis

Differences in categorical variables were analyzed using Fisher's exact test, and those in continuous variables were analyzed using the Mann-Whitney test. Univariate and Multivariate analyses were performed using logistic regression analysis. Multivariate analysis used the significantly different variables detected by the univariate analysis and variables used for classification in the ACCP category and guidelines. The statistical significance level was set at $P < 0.05$. JMP statistics version 14.2.0 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.

Results

Patient characteristics

The flowchart for patient selection is shown in *Figure 3*. A total of 222 consecutive patients with pleural infection were treated between January 2008 and December 2020. Among them, we excluded patients who were diagnosed as showing chronic empyema (n=18), postoperative empyema (n=15), retrograde infection (n=11), pleural infection with *Aspergillus* or tuberculosis (n=9), and empyema after bronchoscopy (n=2). The remaining 167 patients were analyzed.

The patient characteristics are shown in *Table 1*. The median age was 66 years; 139 patients (83.2%) were men, 117 patients (70.1%) were smokers, and 49 patients (29.3%) had received treatment for diabetes mellitus. The median interval from the appearance of symptoms to hospitalization was 7 days (range, 0–74 days).

The causative bacteria were detected by culture or Gram staining in 99 patients (59.3%). *Streptococcus anginosus*




Figure 3 Flowchart for patient selection. Patients were excluded if they were diagnosed with chronic empyema, postoperative empyema, retrograde infection, pleural infection with *Aspergillus* or tuberculosis, or empyema after bronchoscopy. The remaining 167 patients were included in the analyses. To identify the indicators for resistance to non-surgical therapy, patients were divided into two groups; patients cured by non-surgical therapy (n=94) and patients who were resistant to the initial non-surgical treatment (n=73); the latter included patients who underwent surgical intervention after the initial therapy (n=62) and those who showed recurrence or disease-related death after non-surgical therapy (n=11).

was the most frequently detected bacterium (25.7%, 43 patients). Anaerobic bacteria were detected in 38 (22.8%) patients, and a mixed infection of aerobic and anaerobic bacteria was detected in 12 patients (7.2%). β -lactam antibiotics were selected for most of the initial antibiotic treatments (80 patients, 47.9%).

Tube thoracostomy was performed in 157 (94.0%) patients; tube insertion in the remaining 10 (6.0%) patients was difficult because of lung adhesions and a lack of adequate space. Irrigation and thrombolytic therapy with urokinase were performed in 119 (71.3%) and 100 (59.9%) patients, respectively. Surgical intervention was performed in 62 patients (37.1%): 39 patients underwent irrigation, and 23 patients underwent decortication.

Classifications

The data for the variables related to ACCP (17) and Light's classification (8) are shown in Table S1. LAMS was observed in the pleural space anatomy, a single locule, and multiple locules in 38 (22.8%), 100 (59.9%), and 63 (37.7%) patients, respectively. Pleural microbubbles were observed in 38 patients (22.8%), and the split pleura sign was observed

Table 1 Patient characteristics

Variables (n=167)	N (%) or median (range)
Age, years	66 [26–89]
Male	139 (83.2)
Body mass index, kg/m ²	22.6 (12.2–38.4)
ECOG-PS 3–4	19 (11.3)
Smoker	117 (70.1)
Pack-year smoking	17 [0–145]
Heavy drinker	40 (24.0)
From appearance of symptoms to hospitalization (days)	7 [0–74]
PaO ₂ /FiO ₂	341 [63–592]
Comorbidity/anamnesis	
Diabetes mellitus	49 (29.3)
History of malignancy	22 (13.2)
Stroke	17 (10.2)
Chronic kidney disease (creatinine >1.5 mg/dL)	15 (9.0)

Table 1 (continued)

Table 1 (continued)

Variables (n=167)	N (%) or median (range)
Blood test	
C-reactive protein (mg/L)	199 [10–401]
White blood cell (μ L)	14,400 (1,100–75,300)
Albumin (g/dL)	2.5 (1.6–3.9)
Side	
Right	84 (50.3)
Left	83 (49.7)
Detection of causative bacteria in pleural effusion	
Streptococcus anginosus group	43 (25.7)
Anaerobic bacteria	38 (22.8)
Staphylococcus aureus	10 (6.0)
Mixed aerobic and anaerobic bacteria	12 (7.2)
First dose antibiotics	
β -lactamase	80 (47.9)
Carbapenem	58 (34.7)
Piperacillin/Tazobactam	21 (12.6)
Others	8 (4.8)
Procedure	
Tube thoracostomy	157 (94.0)
Irrigation	119 (71.3)
Thrombolytics	100 (59.9)
Surgery	62 (37.1)

ECOG-PS, Eastern Cooperative Oncology Group-performance status.

in 107 patients (64.1%).

Analysis of surgical indications

To identify the indicators for resistance to non-surgical therapy, patients were divided into those cured by non-surgical therapy (n=94) and those resistant to non-surgical therapy (n=73); the latter included patients who underwent surgical intervention after the initial therapy (n=62) and those that showed recurrence or disease-related death after non-surgical therapy (n=11). The characteristics are shown in Table S2.

The findings of the logistic analyses are shown in Table 2. The existence of multiple locules was identified as the only significant variable. The existence of multiple locules without LAMS was a significant variable compared to free-flowing effusion [odds ratio (OR) =3.34, 95% confidence interval (CI): 1.05–10.60, P=0.0409]. The presence of LAMS was a significant indicator compared to a free-flowing effusion (OR =11.47, 95% CI: 3.78–34.78, P<0.0001), single locule (OR =7.70, 95% CI: 3.04–19.48, P<0.0001), and multifocal locules without LAMS (OR =3.43, 95% CI: 1.58–7.97, P=0.0041). Multivariate analysis detected the existence of multiple locules and the presence of LAMS was a significant indicator for resistance to non-surgical therapy.

Treatment courses and prognosis

Treatment courses and prognoses were analyzed by comparing the findings across three groups: patients who underwent surgery within 7 days of admission (n=33), patients who underwent surgery more than 7 days after the admission (n=29), and patients who were treated by non-surgical therapy (n=105) using median days from admission to surgery, as shown in Table S3. Among the prognoses, recurrence of the pleural infection and disease related death were observed only in the non-surgical group. Mortality was not observed among the patients who underwent surgery within 7 days of admission.

The comparisons between patients who underwent surgery within 7 days of admission and patients who underwent surgery more than 7 days after admission are shown in Table 3. Among the patients who underwent surgery within 7 days of admission, the duration of hospitalization was significantly shorter (P=0.0071), and there were significantly more patients whose C-reactive protein level improved within 30 days (P<0.0001).

Discussion

Our study aimed to clarify the predictors for surgical indications in patients with pleural infection and identified that multifocal locules, including LAMS, are significant predictors of resistance to non-surgical therapy in these patients. The American and European guidelines do not specify definite indicators for surgical treatment. The British Thoracic Society guideline proposed a therapeutic algorithm for pleural infection and recommended surgical therapy for patients resistant to antibiotics and chest tube

Table 2 The clinical and image findings of logistic analyses to identify the indicators for resistance to non-surgical therapy in patients with pleural infection (n=167)

Variables	Reference	Univariate analysis			Multivariate analysis		
		OR	95% CI	P	OR	95% CI	P
Age >70 years	≤70 years	0.71	0.48–1.32	0.275			
Sex: male	Female	1.24	0.54–2.85	0.605			
Body mass index >25 kg/m ²	≤25	1.77	0.77–4.05	0.179			
ECOG-PS 3–4	0–2	1.48	0.57–3.86	0.421			
PaO ₂ /FiO ₂ <300	≥300	0.85	0.45–1.60	0.621			
Pack-year smoking>60	≤60	0.56	0.21–1.45	0.232			
Comorbidity/anamnesis							
Diabetes mellitus	No	1.71	0.87–3.34	0.118			
Chronic kidney disease	No	1.53	0.53–4.43	0.434			
From appearance of symptoms to hospitalization >7 days	≤7 days	1.64	0.88–3.03	0.117	1.71	0.84–3.51	0.140
Fistula	No	1.31	0.41–4.25	0.649			
Septic shock at the hospitalization	No	1.31	0.36–4.70	0.680			
Serum albumin level <2.5 g/dL	≥2.5 g/dL	1.02	0.55–1.89	0.946			
White blood cell >15,000/μL	≤15,000/μL	0.79	0.42–1.47	0.461			
CRP >200 mg/L	≤200 mg/L	1.42	0.77–2.62	0.263			
Pus	No	1.11	0.56–2.21	0.755	1.08	0.43–2.70	0.873
Glucose <40 mg/dL (pleural effusion)	≥40 mg/dL	1.11	0.59–2.08	0.743	1.01	0.51–2.37	0.800
pH <7.2 (pleural effusion)	≥7.2	1.53	0.79–2.96	0.211	1.49	0.63–3.50	0.356
Bacteria positive (pleural effusion)	Negative	0.80	0.43–1.48	0.470	0.63	0.29–1.40	0.259
Image findings							
Pleural space anatomy >1/2 hemithorax	≤1/2 hemithorax	1.34	0.71–2.53	0.368	0.81	0.38–1.77	0.608
Locules							
Single locule	Not loculated	0.52	0.44–5.04	0.522	1.73	0.49–6.17	0.397
Multiple locules without LAMS	Not loculated	3.34	1.05–10.60	0.041*	3.67	1.11–12.14	0.033*
	Single locule	2.24	0.84–5.99	0.108	2.12	0.72–6.21	0.171
Multiple locules + LAMS	Not loculated	11.47	3.78–34.78	<0.001*	14.15	4.30–46.56	<0.001*
	Single locule	7.70	3.04–19.48	<0.001*	8.17	3.06–21.82	<0.001*
	Multiple locules without LAMS	3.43	1.58–7.97	0.0041*	3.86	1.52–9.77	0.0044*
Microbubbles	No	1.06	0.51–2.19	0.885			
Split Pleural Sign	No	1.57	0.82–3.01	0.171			

*, significant difference (P<0.05). OR, odds ratios; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group-performance status; LAMS, locule on the anterior mediastinum side; CRP, C-reactive protein.

Table 3 Comparison of the treatment and prognosis between the patients who treated underwent surgery within 7 days and over 7 days of admission

Outcome	Surgery \leq 7 days (n=33)	Surgery >7 days (n=29)	P value
Duration between admission and surgery (average, days)	2.9	18.6	
Hospitalization (average, days)	26.9	42.0	0.0071*
Using antibiotics (average, days)	31.0	38.5	0.0619
Duration of CRP improvement <30 days, n (%)	23 (69.7)	6 (20.7)	<0.0001*
Recurrence of empyema, n (%)	0 (0.0)	0 (0.0)	0.2480

Surgery \leq 7 days: patients underwent surgery within 7 days of admission; surgery >7 days: patients underwent surgery over 7 days of admission; duration of CRP improvement: CRP level improved within 10 mg/L during the observation period. *, significant difference ($P<0.05$). CRP, C-reactive protein.

replacement (1). The guideline of the American Association for Thoracic Surgery recommends chest tube replacement followed by surgical management for the patients showing pus, positive results in culture or Gram staining, and a pleural fluid pH<7.2, based on the classifications of Light and the ACCP (4,17). Conversely, Himelman *et al.* reported that Light's classification was unreliable in patients with locules because the bacteriological and chemical findings of locules in patients with multiple locules are not consistent (9). Consistent with this result, Everts *et al.* found that 44% of culture findings from catheters or chest tubes were inaccurate; this suggested that the direct aspiration of the potentially infected locules is important (10). Maskell *et al.* reported differences in the chemical and bacteriological findings for locules in patients with multiloculated pleural infections (11). These reports suggest that negative findings in bacteriological and chemical examinations on thoracentesis are not a definitive factor for excluding surgical procedures from the potential treatment options. Therefore, to detect the existence of a locule with uncontrolled infection (18), imaging results may be valid predictors of resistance to the medical treatment. Many previous studies concluded that multifocal locules on ultrasonography and CT scans predicted surgical management (19). In our study, LAMS, which has not been discussed previously, was a strong indicator for surgical management, because chest tube drainage is quite difficult and thrombolytic therapy may not be effective on the anterior mediastinal side. There is no report about the anatomical positional relationship of the locules and resistance of the non-surgical therapy, the results of this study may be useful for establishing criteria for surgical indication. As ultrasonography has difficulty observing the thoracic cavity on the anterior mediastinum side, the

presence of LAMS on the CT scan should be confirmed before a decision is made for the treatment of a pleural infection.

We clarified that early surgery within 7 days of admission could decrease the duration of hospitalization and improved C-reactive protein level faster, which suggests that early consultation with a thoracic surgeon and surgery in patients with these imaging results may improve the prognosis; this is contrary to the conventional guidelines of surgical treatment for the pleural infections resistant to initial non-surgical treatment. The prognosis of a pleural infection remains poor, with a mortality rate of 15–20% (1,2) and long-term hospitalization (20). Possible causes include uncontrolled infection and recurrence of respiratory infections. Tube drainage does not always remove the fluid completely, especially in patients with multiple locules. These drainage-defective cavities may cause uncontrolled infection and recurrence of the pleural infection. Moreover, the lungs are often not fully dilated at discharge in patients with tube drainage, which might induce pneumonia at the site of the poor lung dilation and respiratory failure due to decreased lung function. Wozniak *et al.* reported that the first choice for management of empyema was strongly related to the prognosis (13). A USA database analysis of patients with pleural infection who had received chest tube drainage showed that they had higher rates of mortality, re-admission, and re-intervention compared with patients who had received surgical treatment (12). These conclusions suggest that earlier surgical management for selected patients with pleural infections can reduce the duration of hospitalization and even improve the prognosis of pleural infection (21,22), because adequate surgical intervention can unify the thoracic cavity and promote sufficient lung dilation (2). In this study, none of the patients who

underwent surgery showed recurrence of empyema, and the rate of disease-related death among these patients was lower than that among patients who received non-surgical treatment. The selection of the appropriate patients with pleural infections will require a determination of the indicators for surgical conversion or the need for surgery.

Nayak *et al.* demonstrated that the inpatient mortality rate for VATS decreased over time (7% until 2011 to 4.3% after 2011) (21), which suggests that the VATS procedure is less invasive and more stable. VATS for pleural infections was reported to reduce the operative time, postoperative pain, duration of chest tube drainage and hospitalization, and mortality rate (22,23). The stereotype that surgical treatment is highly invasive should be dispelled; it has been suggested that surgery benefits patients with pleural infections (24). Since various factors such as causative bacteria, duration of illness, and comorbidities may contribute to the progression of intrathoracic infections such as a pleural infection (25,26), the treatment strategy cannot be determined easily. We propose that surgical indicators such as LAMS are simple and will help determine early consultation with surgeons. Early surgery for patients with these imaging results may improve the prognosis of pleural infections.

Since the present study was a retrospective and single-center analysis, the number of patients was small and there were biases related to treatment methods and patient groups. Combination therapy using tissue plasminogen activator and DNase could not undergo and only monotherapy using urokinase was performed in our facility, some patients who underwent surgery may treat using combination therapy. Moreover, this study spanned over a long period during which changes in practices and thresholds to refer patients to surgery may have evolved. This analysis did not include the patients with a poor general condition who clearly were not indicated for surgery, and a selection bias may have existed. Therefore, multicenter studies with large sample sizes are required to construct a more definitive strategy.

Conclusions

Multifocal locules, including LAMS, were valid indicators for surgical management in patients with pleural infections. Early surgery for patients with these findings may shorten hospital stay and improve the prognosis of pleural infections.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1812/rc>

Data Sharing Statement: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1812/dss>

Peer Review File: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1812/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-21-1812/coif>). AI serves as an unpaid editorial board member of *Journal of Thoracic Disease* from May 2019 to April 2021. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by ethics committee of Toho University Omori Medical Center (No. M20218_19218) and informed consent was taken from all the patients.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Davies HE, Davies RJ, Davies CW, et al. Management of pleural infection in adults: British Thoracic Society Pleural

- Disease Guideline 2010. *Thorax* 2010;65 Suppl 2:ii41-53.
2. Shen KR, Bribriescio A, Crabtree T, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. *J Thorac Cardiovasc Surg* 2017;153:e129-46.
 3. Andrews NC. Management of nontuberculous empyema: A statement of the subcommittee on surgery. *Am Rev Respir Dis* 1962;85:935.
 4. Light RW. A new classification of parapneumonic effusions and empyema. *Chest* 1995;108:299-301.
 5. Weissberg D, Refaely Y. Pleural empyema: 24-year experience. *Ann Thorac Surg* 1996;62:1026-9.
 6. Roberts JR. Minimally invasive surgery in the treatment of empyema: intraoperative decision making. *Ann Thorac Surg* 2003;76:225-30; discussion 229-30.
 7. Light RW. Parapneumonic effusions and empyema. *Clin Chest Med* 1985;6:55-62.
 8. Light RW. Parapneumonic effusions and empyema. *Proc Am Thorac Soc* 2006;3:75-80.
 9. Himelman RB, Callen PW. The prognostic value of loculations in parapneumonic pleural effusions. *Chest* 1986;90:852-6.
 10. Everts RJ, Heneghan JP, Adholla PO, et al. Validity of cultures of fluid collected through drainage catheters versus those obtained by direct aspiration. *J Clin Microbiol* 2001;39:66-8.
 11. Maskell NA, Gleeson FV, Darby M, et al. Diagnostically significant variations in pleural fluid pH in loculated parapneumonic effusions. *Chest* 2004;126:2022-4.
 12. Semenkovich TR, Olsen MA, Puri V, et al. Current State of Empyema Management. *Ann Thorac Surg* 2018;105:1589-96.
 13. Wozniak CJ, Paull DE, Moezzi JE, et al. Choice of first intervention is related to outcomes in the management of empyema. *Ann Thorac Surg* 2009;87:1525-30; discussion 1530-1.
 14. Smolikov A, Smolyakov R, Riesenberk K, et al. Prevalence and clinical significance of pleural microbubbles in computed tomography of thoracic empyema. *Clin Radiol* 2006;61:513-9.
 15. Kraus GJ. The split pleura sign. *Radiology* 2007;243:297-8.
 16. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. *N Engl J Med* 2011;365:518-26.
 17. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. *Chest* 2000;118:1158-71.
 18. Ravaglia C, Gurioli C, Tomassetti S, et al. Is medical thoracoscopy efficient in the management of multiloculated and organized thoracic empyema?. *Respiration* 2012;84:219-24.
 19. Chen KY, Liaw YS, Wang HC, et al. Sonographic septation: a useful prognostic indicator of acute thoracic empyema. *J Ultrasound Med* 2000;19:837-43.
 20. Cargill TN, Hassan M, Corcoran JP, et al. A systematic review of comorbidities and outcomes of adult patients with pleural infection. *Eur Respir J* 2019;54:1900541.
 21. Nayak R, Brogly SB, Lajkosz K, et al. Outcomes of Operative and Nonoperative Treatment of Thoracic Empyema: A Population-Based Study. *Ann Thorac Surg* 2019;108:1456-63.
 22. Redden MD, Chin TY, van Driel ML. Surgical versus non-surgical management for pleural empyema. *Cochrane Database Syst Rev* 2017;3:CD010651.
 23. Chambers A, Routledge T, Dunning J, et al. Is video-assisted thoracoscopic surgical decortication superior to open surgery in the management of adults with primary empyema? *Interact Cardiovasc Thorac Surg* 2010;11:171-7.
 24. Scarci M, Abah U, Solli P, et al. EACTS expert consensus statement for surgical management of pleural empyema. *Eur J Cardiothorac Surg* 2015;48:642-53.
 25. Sakai T, Sano A, Azuma Y, et al. Streptococcus anginosus group infection as a predictor for the progression of descending necrotizing mediastinitis. *Ann Palliat Med* 2021;10:4008-16.
 26. Sakai T, Sano A, Azuma Y, et al. Preoperative undernutrition predicts postoperative complications of acute empyema. *Health Sci Rep* 2021;4:e232.

Cite this article as: Sakai T, Sano A, Shimizu H, Azuma Y, Urabe N, Isobe K, Sakamoto S, Takai Y, Murakami Y, Kishi K, Iyoda A. Multifocal locules including the anterior mediastinum side as a surgical indicator in pleural infection. *J Thorac Dis* 2022;14(6):1990-1999. doi: 10.21037/jtd-21-1812

Table S1 Variables related to the ACCP and Light's classifications

Variables (n=167)	n	%
Anatomy		
10 mm < and 1/2 hemithorax	107	64.1
>1/2 hemithorax	60	35.9
Free flowing	29	17.4
Single locule	38	22.8
Multilocular	100	59.9
LAMS	63	37.7
Pleural microbubbles	38	22.8
Sprit pleura sign	107	64.1
Bacteriology		
Negative	61	36.5
Positive (not pus)	60	35.9
Pus	46	27.5
Chemistry		
pH: not detected	63	37.7
pH \geq 7.20	53	31.7
pH <7.20	51	30.5
Glucose <40 mg/dL	64	38.3
LDH >1,000 IU/L	90	53.9
ACCP category		
2	14	8.4
3	107	64.1
4	46	27.5
Light classification		
2-3	21	13.6
4-5	100	59.9
6-7	46	27.6

ACCP, American College of Chest Physicians; LAMS, locule in the anterior mediastinum side.

Table S2 The clinical and image findings of patients with pleural infection who cured by non-surgical therapy (n=94) and who resistant to non-surgical therapy (n=73)

Variables	Cured by non-surgical therapy (n=94)	Resistant to non-surgical therapy (n=73)	P
Age >70 years	50 (53)	45 (62)	0.273
Sex: male	77 (82)	62 (85)	0.603
Body mass index >25	12 (13)	15 (21)	0.177
ECOG-PS 3–4	9 (10)	10 (14)	0.421
PaO ₂ /FiO ₂ <300	37 (39)	26 (36)	0.620
Pack-year smoking>60	15 (16)	7 (10)	0.221
Comorbidity/anamnesis			
Diabetes mellitus	23 (24)	26 (36)	0.117
Chronic kidney disease	7 (7)	8 (11)	0.433
From appearance of symptoms to hospitalization >7 days	40 (43)	40 (55)	0.116
Fistula	6 (6)	6 (8)	0.650
Septic shock at the hospitalization	5 (5)	5 (7)	0.680
Serum albumin level <2.5 g/dL	42 (45)	33 (45)	0.946
WBC >15,000/μL	44 (47)	30 (41)	0.461
CRP >200 mg/L	42 (45)	39 (53)	0.262
Pus	25 (27)	21 (29)	0.756
Glucose <40 mg/dL (pleural effusion)	35 (37)	29 (40)	0.743
pH <7.2 (pleural effusion)	25 (27)	26 (36)	0.210
Bacteria positive (pleural effusion)	58 (62)	41 (56)	0.470
Image findings	58 (62)	41 (56)	0.470
Pleural space anatomy >1/2 hemithorax	31 (33)	29 (40)	0.370
Locules			<0.001*
Single locule	29 (31)	9 (12)	
Multiple locules without LAMS	23 (25)	16 (22)	
Multiple locules + LAMS	18 (19)	43 (59)	
Microbubbles	21 (22)	17 (23)	0.885
Split pleural sign	56 (60)	51 (70)	0.168

All variables are number (%). ECOG-PS, Eastern Cooperative Oncology Group-performance status; CRP, C-reactive protein; WBC, white blood cells; LAMS, locule on the anterior mediastinum side.

Table S3 Treatment courses and prognosis were analysed by comparing the findings across three groups: patients who underwent surgery within 7 days of admission (n=33), the patients who underwent surgery more than 7 days after the admission (n=29), and patients who treated by non-surgical therapy (n=105)

Variables/outcome	Surgery ≤7 days (n=33)	Surgery >7 days (n=29)	Non-surgery (n=105)
Age (average, range)	61.8±14.0	57.8±15.0	67.8±13.6
ECOG-PS 3–4	12.1% (4)	13.8% (4)	10.6% (11)
From appearance of symptoms to hospitalization	15.0±13.9	11.6±9.6	10.8±12.0
Septic shock at the hospitalization	9.1% (3)	6.9% (2)	6.0% (5)
Hospitalization (average, days)	26.9±12.4	42.0±28.1	32.6±23.5
Using antibiotics (average, days)	31.0±14.2	38.5±16.9	38.9±24.3
Duration of tube placement (average, days)	16.7±6.4	23.9±11.9	18.2±13.6
CRP improved <1.0 mg/dL <30 days	69.7% (23)	20.7% (6)	49.5% (52)
CRP improved <1.0 mg/dL during the observation period	96.7% (32)	82.8% (24)	83.8% (88)
Recurrence of empyema, % (n)	0.0% (0)	0.0% (0)	2.9% (3)
Disease related death in 3 month, % (n)	0.0% (0)	0.0% (0)	2.9% (3)
3-month mortality, % (n)	0.0% (0)	3.5% (1)	5.7% (6)
6-month mortality, % (n)	0.0% (0)	6.9% (2)	11.4% (12)

Surgery ≤7 days: patients underwent surgery within 7 days of admission; surgery >7 days: patients underwent surgery over 7 days of admission; non-surgery: patients who treated by non-surgical therapy. CRP, C-reactive protein; ECOG-PS, Eastern Cooperative Oncology Group-performance status.